PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism

Vu, John P.; Luong, Leon; Sanford, Daniel; Oh, Suwan; A, Kuć; Pisegna, Rita; Lewis, Michael; Pisegna, Joseph R.; Germano, Patrizia M.

doi:10.3390/biology12071013

Cited by 4 publications

(1 citation statement)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, these mice had decreased body weight compared to that of their wild-type littermates due to a decreased amount of WAT [ 154 ]. Even though PACAP is involved in the regulation of energy homeostasis and could be considered a possible target for obesity treatment, the direct antiobesity effects of PACAP have still not been well explored [ 155 ].…”

Section: Anorexigenic Neuropeptidesmentioning

confidence: 99%

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

Strnadová,

Pačesová,

Charvát

et al. 2024

Bioscience Reports

View full text Add to dashboard Cite

Since 1975, the incidence of obesity has increased to epidemic proportions, and the number of patients with obesity has quadrupled. Obesity is a major risk factor for developing other serious diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Recent epidemiologic studies have defined obesity as a risk factor for the development of neurodegenerative diseases, such as Alzheimer's disease (AD) and other types of dementia. Despite all these serious comorbidities associated with obesity, there is still a lack of effective antiobesity treatment. Promising candidates for the treatment of obesity are anorexigenic neuropeptides, which are peptides produced by neurons in brain areas implicated in food intake regulation, such as the hypothalamus or the brainstem. These peptides efficiently reduce food intake and body weight. Moreover, because of the proven interconnection between obesity and the risk of developing AD, the potential neuroprotective effects of these two agents in animal models of neurodegeneration have been examined. The objective of this review was to explore anorexigenic neuropeptides produced and acting within the brain, emphasizing their potential not only for the treatment of obesity but also for the treatment of neurodegenerative disorders.

show abstract

Section: Anorexigenic Neuropeptidesmentioning

confidence: 99%

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

Strnadová,

Pačesová,

Charvát

et al. 2024

Bioscience Reports

View full text Add to dashboard Cite

show abstract

The role of NPY signaling pathway in diagnosis, prognosis and treatment of stroke

Jiang,

Zheng,

et al. 2024

Neuropeptides

View full text Add to dashboard Cite

PACAP ameliorates obesity‐induced insulin resistance through FAIM/Rictor/AKT axis

Feng,

Chen,

et al. 2024

The FEBS Journal

View full text Add to dashboard Cite

Obesity and obesity‐related insulin resistance have been a research hotspot. Pituitary adenylate cyclase activating polypeptide (PACAP) has emerged as playing a significant role in energy metabolism, holding promising potential for attenuating insulin resistance. However, the precise mechanism is not fully understood. Palmitic acid and a high‐fat diet (HFD) were used to establish insulin resistance model in Alpha mouse liver 12 cell line and C57BL/6 mice, respectively. Subsequently, we assessed the effects of PACAP both in vivo and in vitro. Lentivirus vectors were used to explore the signaling pathway through which PACAP may ameliorate insulin resistance. PACAP was found to selectively bind to the PACAP type I receptor receptor and ameliorate insulin resistance, which was characterized by increased glycogen synthesis and the suppression of gluconeogenesis in the insulin‐resistant cell model and HFD‐fed mice. These effects were linked to the activation of the Fas apoptotic inhibitory molecule/rapamycin‐insensitive companion of mammalian target of rapamycin/RAC‐alpha serine/threonine‐protein kinase (FAIM/Rictor/AKT) axis. Furthermore, PACAP ameliorated insulin resistance by increasing solute carrier family 2, facilitated glucose transporter members 2/4 and inhibiting gluconeogenesis‐related proteins glucose 6‐phosphatase catalytic subunit 1 and phosphoenolpyruvate carboxykinase 2 expression. Meanwhile, the phosphorylation of hepatic AKT/glycogen synthase kinase 3β was promoted both in vivo and in vitro by PACAP. Additionally, PACAP treatment decreased body weight, food intake and blood glucose levels in obese mice. Our study shows that PACAP ameliorated insulin resistance through the FAIM/Rictor/AKT axis, presenting it as a promising drug candidate for the treatment of obesity‐related insulin resistance.

show abstract

PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism

Cited by 4 publications

References 107 publications

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents

The role of NPY signaling pathway in diagnosis, prognosis and treatment of stroke

PACAP ameliorates obesity‐induced insulin resistance through FAIM/Rictor/AKT axis

Contact Info

Product

Resources

About